Stress Induced Hyperglycemia in the Context of Acute Coronary Syndrome: Definitions, Interventions, and Underlying Mechanisms

Mingmin Li, Guo Chen, Yingqing Feng, Xuyu He, Mingmin Li, Guo Chen, Yingqing Feng, Xuyu He

Abstract

Elevation of glucose level in response to acute coronary syndrome (ACS) has been recognized as stress induced hyperglycemia (SIH). Plenty of clinical studies have documented that SIH occurs very common in patients hospitalized with ACS, even in those without previously known diabetes mellitus. The association between elevated blood glucose levels with adverse outcome in the ACS setting is well-established. Yet, the precise definition of SIH in the context of ACS remains controversial, bringing confusions about clinical management strategy. Several randomized trials aimed to evaluate the effect of insulin-based therapy on outcomes of ACS patients failed to demonstrate a consistent benefit of intensive glucose control. Mechanisms underlying detrimental effects of SIH on patients with ACS are undetermined, oxidative stress might play an important role in the upstream pathways leading to subsequent harmful effects on cardiovascular system. This review aims to discuss various definitions of SIH and their values in predicting adverse outcome in the context of ACS, as well as the effect of intensive glucose control on clinical outcome. Finally, a glimpse of the underlying mechanisms is briefly discussed.

Keywords: acute coronary syndrome; admission blood glucose; intensive glucose control; oxidative stress; stress induced hyperglycemia.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Li, Chen, Feng and He.

Figures

Figure 1
Figure 1
Postulated mechanisms underlying detrimental effects of SIH.

References

    1. Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet. (2000) 355:773–8. 10.1016/S0140-6736(99)08415-9
    1. Oswald G, Corcoran S, Yudkin J. Prevalence and risks of hyperglycaemia and undiagnosed diabetes in patients with acute myocardial infarction. Lancet. (1984) 323:1264–7. 10.1016/S0140-6736(84)92447-4
    1. Datey KK, Nanda NC. Hyperglycemia after acute myocardial infarction. Its relation to diabetes mellitus. N Engl J Med. (1967) 276:262–5. 10.1056/NEJM196702022760504
    1. Kosiborod M, Rathore SS, Inzucchi SE, Masoudi FA, Wang Y, Havranek EP, et al. . Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes. Circulation. (2005) 111:3078–86. 10.1161/CIRCULATIONAHA.104.517839
    1. Kadri Z, Danchin N, Vaur L, Cottin Y, Gueret P, Zeller M, et al. . Major impact of admission glycaemia on 30 day and one year mortality in non-diabetic patients admitted for myocardial infarction: results from the nationwide French USIC 2000 study. Heart. (2006) 92:910–5. 10.1136/hrt.2005.073791
    1. Deedwania P, Kosiborod M, Barrett E, Ceriello A, Isley W, Mazzone T, et al. . Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. (2008) 117:1610–9. 10.1161/CIRCULATIONAHA.107.188629
    1. Kosiborod M, Inzucchi SE, Krumholz HM, Xiao L, Jones PG, Fiske S, et al. . Glucometrics in patients hospitalized with acute myocardial infarction: defining the optimal outcomes-based measure of risk. Circulation. (2008) 117:1018–27. 10.1161/CIRCULATIONAHA.107.740498
    1. Hao Y, Lu Q, Li T, Yang G, Hu P, Ma A. Admission hyperglycemia and adverse outcomes in diabetic and non-diabetic patients with non-ST-elevation myocardial infarction undergoing percutaneous coronary intervention. BMC Cardiovasc Disord. (2017) 17:6. 10.1186/s12872-016-0441-x
    1. Liao WI, Lin CS, Lee CH, Wu YC, Chang WC, Hsu CW, et al. . An elevated glycemic gap is associated with adverse outcomes in diabetic patients with acute myocardial infarction. Sci Rep. (2016) 6:27770. 10.1038/srep27770
    1. Kojima T, Hikoso S, Nakatani D, Suna S, Dohi T, Mizuno H, et al. . Impact of hyperglycemia on long-term outcome in patients with ST-segment elevation myocardial infarction. Am J Cardiol. (2020) 125:851–9. 10.1016/j.amjcard.2019.12.034
    1. Bellodi G, Manicardi V, Malavasi V, Veneri L, Bernini G, Bossini P, et al. . Hyperglycemia and prognosis of acute myocardial infarction in patients without diabetes mellitus. Am J Cardiol. (1989) 64:885–8. 10.1016/0002-9149(89)90836-9
    1. Foo K, Cooper J, Deaner A, Knight C, Suliman A, Ranjadayalan K, et al. . A single serum glucose measurement predicts adverse outcomes across the whole range of acute coronary syndromes. Heart. (2003) 89:512–6. 10.1136/heart.89.5.512
    1. Ritsinger V, Jensen J, Ohm D, Omerovic E, Koul S, Frobert O, et al. . Elevated admission glucose is common and associated with high short-term complication burden after acute myocardial infarction: insights from the VALIDATE-SWEDEHEART study. Diab Vasc Dis Res. (2019) 16:582–4. 10.1177/1479164119871540
    1. Goyal A, Mahaffey KW, Garg J, Nicolau JC, Hochman JS, Weaver WD, et al. . Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study. Eur Heart J. (2006) 27:1289–97. 10.1093/eurheartj/ehi884
    1. Buturlin K, Minha S, Rozenbaum Z, Neuman Y, Shlezinger M, Goldenberg I, et al. . Admission plasma glucose levels within the normal to mildly impaired range and the outcome of patients with acute coronary syndrome. Eur Heart J Acute Cardiovasc Care. (2017) 6:738–43. 10.1177/2048872616641900
    1. Roberts GW, Quinn SJ, Valentine N, Alhawassi T, O'Dea H, Stranks SN, et al. . Relative hyperglycemia, a marker of critical illness: introducing the stress hyperglycemia ratio. J Clin Endocrinol Metab. (2015) 100:4490–7. 10.1210/jc.2015-2660
    1. Marenzi G, Cosentino N, Milazzo V, De Metrio M, Cecere M, Mosca S, et al. . Prognostic value of the acute-to-chronic glycemic ratio at admission in acute myocardial infarction: a prospective study. Diabetes Care. (2018) 41:847–53. 10.2337/dc17-1732
    1. Chen PC, Tsai SH, Wang JC, Tzeng YS, Wang YC, Chu CM, et al. . An elevated glycemic gap predicts adverse outcomes in diabetic patients with necrotizing fasciitis. PLoS ONE. (2019) 14:e0223126. 10.1371/journal.pone.0223126
    1. Gao S, Liu Q, Ding X, Chen H, Zhao X, Li H. Predictive value of the acute-to-chronic glycemic ratio for in-hospital outcomes in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. Angiology. (2020) 71:38–47. 10.1177/0003319719875632
    1. Yang Y, Kim TH, Yoon KH, Chung WS, Ahn Y, Jeong MH, et al. . The stress hyperglycemia ratio, an index of relative hyperglycemia, as a predictor of clinical outcomes after percutaneous coronary intervention. Int J Cardiol. (2017) 241:57–63. 10.1016/j.ijcard.2017.02.065
    1. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, et al. . Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. (2006) 295:1681–7. 10.1001/jama.295.14.1681
    1. Ceriello A, Esposito K, Piconi L, Ihnat MA, Thorpe JE, Testa R, et al. . Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes. (2008) 57:1349–54. 10.2337/db08-0063
    1. Krinsley JS. Glycemic variability: a strong independent predictor of mortality in critically ill patients. Crit Care Med. (2008) 36:3008–13. 10.1097/CCM.0b013e31818b38d2
    1. Su G, Mi SH, Tao H, Li Z, Yang HX, Zheng H, et al. . Impact of admission glycemic variability, glucose, and glycosylated hemoglobin on major adverse cardiac events after acute myocardial infarction. Diabetes Care. (2013) 36:1026–32. 10.2337/dc12-0925
    1. Mi SH, Su G, Yang HX, Zhou Y, Tian L, Zhang T, et al. . Comparison of in-hospital glycemic variability and admission blood glucose in predicting short-term outcomes in non-diabetes patients with ST elevation myocardial infarction underwent percutaneous coronary intervention. Diabetol Metab Syndr. (2017) 9:20. 10.1186/s13098-017-0217-1
    1. Takahashi H, Iwahashi N, Kirigaya J, Kataoka S, Minamimoto Y, Gohbara M, et al. . Glycemic variability determined with a continuous glucose monitoring system can predict prognosis after acute coronary syndrome. Cardiovasc Diabetol. (2018) 17:116. 10.1186/s12933-018-0761-5
    1. Gerbaud E, Darier R, Montaudon M, Beauvieux MC, Coffin-Boutreux C, Coste P, et al. . Glycemic variability is a powerful independent predictive factor of midterm major adverse cardiac events in patients with diabetes with acute coronary syndrome. Diabetes Care. (2019) 42:674–81. 10.2337/dc18-2047
    1. Pu Z, Lai L, Yang X, Wang Y, Dong P, Wang D, et al. . Acute glycemic variability on admission predicts the prognosis in hospitalized patients with coronary artery disease: a meta-analysis. Endocrine. (2020) 67:526–34. 10.1007/s12020-019-02150-1
    1. Siegelaar SE, Holleman F, Hoekstra JB, DeVries JH. Glucose variability; does it matter? Endocr Rev. (2010) 31:171–82. 10.1210/er.2009-0021
    1. Bergenstal RM. Glycemic variability and diabetes complications: does it matter? Simply put, there are better glycemic markers! Diabetes Care. (2015) 38:1615–21. 10.2337/dc15-0099
    1. Suleiman M, Hammerman H, Boulos M, Kapeliovich MR, Suleiman A, Agmon Y, et al. . Fasting glucose is an important independent risk factor for 30-day mortality in patients with acute myocardial infarction: a prospective study. Circulation. (2005) 111:754–60. 10.1161/01.CIR.0000155235.48601.2A
    1. Aronson D, Hammerman H, Kapeliovich MR, Suleiman A, Agmon Y, Beyar R, et al. . Fasting glucose in acute myocardial infarction: incremental value for long-term mortality and relationship with left ventricular systolic function. Diabetes Care. (2007) 30:960–6. 10.2337/dc06-1735
    1. Ye N, Yang L, Wang G, Bian W, Xu F, Ma C, et al. . Admission fasting plasma glucose is associated with in-hospital outcomes in patients with acute coronary syndrome and diabetes: findings from the improving care for cardiovascular disease in China—acute coronary syndrome (CCC-ACS) project. BMC Cardiovasc Disord. (2020) 20:380. 10.1186/s12872-020-01662-3
    1. Malmberg K, Rydén L, Efendic S, Herlitz J, Nicol P, Waldenstrom A, et al. . Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol. (1995) 26:57–65. 10.1016/0735-1097(95)00126-K
    1. Malmberg K, Norhammar A, Wedel H, Ryden L. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the diabetes and insulin-glucose infusion in acute myocardial infarction (DIGAMI) study. Circulation. (1999) 99:2626–32. 10.1161/01.CIR.99.20.2626
    1. Malmberg K, Ryden L, Wedel H, Birkeland K, Bootsma A, Dickstein K, et al. . Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J. (2005) 26:650–61. 10.1093/eurheartj/ehi199
    1. Cheung NW, Wong VW, McLean M. The hyperglycemia: intensive insulin infusion in infarction (HI-5) study: a randomized controlled trial of insulin infusion therapy for myocardial infarction. Diabetes Care. (2006) 29:765–70. 10.2337/diacare.29.04.06.dc05-1894
    1. Nerenberg KA, Goyal A, Xavier D, Sigamani A, Ng J, Mehta SR, et al. . Piloting a novel algorithm for glucose control in the coronary care unit: the RECREATE (researching coronary reduction by appropriately targeting euglycemia) trial. Diabetes Care. (2012) 35:19–24. 10.2337/dc11-0706
    1. Marfella R, Di Filippo C, Portoghese M, Ferraraccio F, Rizzo MR, Siniscalchi M, et al. . Tight glycemic control reduces heart inflammation and remodeling during acute myocardial infarction in hyperglycemic patients. J Am Coll Cardiol. (2009) 53:1425–36. 10.1016/j.jacc.2009.01.041
    1. Marfella R, Sasso FC, Siniscalchi M, Paolisso P, Rizzo MR, Ferraro F, et al. . Peri-procedural tight glycemic control during early percutaneous coronary intervention is associated with a lower rate of in-stent restenosis in patients with acute ST-elevation myocardial infarction. J Clin Endocrinol Metab. (2012) 97:2862–71. 10.1210/jc.2012-1364
    1. Marfella R, Rizzo MR, Siniscalchi M, Paolisso P, Barbieri M, Sardu C, et al. . Peri-procedural tight glycemic control during early percutaneous coronary intervention up-regulates endothelial progenitor cell level and differentiation during acute ST-elevation myocardial infarction: effects on myocardial salvage. Int J Cardiol. (2013) 168:3954–62. 10.1016/j.ijcard.2013.06.053
    1. de Mulder M, Umans VA, Cornel JH, van der Zant FM, Stam F, Oemrawsingh RM, et al. . Intensive glucose regulation in hyperglycemic acute coronary syndrome: results of the randomized BIOMarker study to identify the acute risk of a coronary syndrome-2 (BIOMArCS-2) glucose trial. JAMA Intern Med. (2013) 173:1896–904. 10.1001/jamainternmed.2013.10074
    1. van den Berg VJ, Umans VA, Stam F, de Mulder M, Akkerhuis KM, Cornel JH, et al. . Long-term follow-up of the randomized (BIOMArCS-2) glucose trial: intensive glucose regulation in hyperglycemic acute coronary syndrome. Circulation. (2016) 134:984–6. 10.1161/CIRCULATIONAHA.116.023480
    1. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. . Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. (2019) 380:347–57. 10.1056/NEJMoa1812389
    1. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. . Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. (2015) 373:2117–28. 10.1056/NEJMoa1504720
    1. Bethel MA, Patel RA, Merrill P, Lokhnygina Y, Buse JB, Mentz RJ, et al. . Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. (2018) 6:105–13. 10.1016/S2213-8587(17)30412-6
    1. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes. (2005) 54:146–51. 10.2337/diabetes.54.1.146
    1. Sonne DP, Engstrom T, Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept. (2008) 146:243–9. 10.1016/j.regpep.2007.10.001
    1. Lahnwong S, Palee S, Apaijai N, Sriwichaiin S, Kerdphoo S, Jaiwongkam T, et al. . Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia/reperfusion injury. Cardiovasc Diabetol. (2020) 19:91. 10.1186/s12933-020-01066-9
    1. Lee TM, Chang NC, Lin SZ. Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med. (2017) 104:298–310. 10.1016/j.freeradbiomed.2017.01.035
    1. Tanajak P, Sa-Nguanmoo P, Sivasinprasasn S, Thummasorn S, Siri-Angkul N, Chattipakorn SC, et al. . Cardioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia-reperfusion injury. J Endocrinol. (2018) 236:69–84. 10.1530/JOE-17-0457
    1. Lonborg J, Vejlstrup N, Kelbaek H, Botker HE, Kim WY, Mathiasen AB, et al. . Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J. (2012) 33:1491–9. 10.1093/eurheartj/ehr309
    1. Chen WR, Chen YD, Tian F, Yang N, Cheng LQ, Hu SY, et al. . Effects of liraglutide on reperfusion injury in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Imaging. (2016) 9:146. 10.1161/CIRCIMAGING.116.005146
    1. Chen WR, Hu SY, Chen YD, Zhang Y, Qian G, Wang J, et al. . Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am Heart J. (2015) 170:845–54. 10.1016/j.ahj.2015.07.014
    1. Chen WR, Shen XQ, Zhang Y, Chen YD, Hu SY, Qian G, et al. . Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction. Endocrine. (2016) 52:516–26. 10.1007/s12020-015-0798-0
    1. Lan NSR, Yeap BB, Fegan PG, Green G, Rankin JM, Dwivedi G. Empagliflozin and left ventricular diastolic function following an acute coronary syndrome in patients with type 2 diabetes. Int J Cardiovasc Imaging. (2021) 37:517–27. 10.1007/s10554-020-02034-w
    1. Corbett SJ. NICE recommendations for the management of hyperglycaemia in acute coronary syndrome. Heart. (2012) 98:1189–91. 10.1136/heartjnl-2012-302421
    1. Collet JP, Thiele H, Barbato E, Barthelemy O, Bauersachs J, Bhatt DL, et al. . 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. (2021) 42:1289–367. 10.1093/eurheartj/ehaa575
    1. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. . 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. (2018) 39:119–77. 10.1093/eurheartj/ehx393
    1. Dungan KM, Braithwaite SS, Preiser J-C. Stress hyperglycaemia. Lancet. (2009) 373:1798–807. 10.1016/S0140-6736(09)60553-5
    1. Bellis A, Mauro C, Barbato E, Ceriello A, Cittadini A, Morisco C. Stress-induced hyperglycaemia in non-diabetic patients with acute coronary syndrome: from molecular mechanisms to new therapeutic perspectives. Int J Mol Sci. (2021) 22:775. 10.3390/ijms22020775
    1. Wallander M, Bartnik M, Efendic S, Hamsten A, Malmberg K, Ohrvik J, et al. . Beta cell dysfunction in patients with acute myocardial infarction but without previously known type 2 diabetes: a report from the GAMI study. Diabetologia. (2005) 48:2229–35. 10.1007/s00125-005-1931-z
    1. Bartnik M, Malmberg K, Hamsten A, Efendic S, Norhammar A, Silveira A, et al. . Abnormal glucose tolerance–a common risk factor in patients with acute myocardial infarction in comparison with population-based controls. J Intern Med. (2004) 256:288–97. 10.1111/j.1365-2796.2004.01371.x
    1. Vanhorebeek I, Van den Berghe G. Diabetes of injury: novel insights. Endocrinol Metab Clin North Am. (2006) 35:859–72, x. 10.1016/j.ecl.2006.09.002
    1. Shamoon H, Hendler R, Sherwin RS. Synergistic interactions among antiinsulin hormones in the pathogenesis of stress hyperglycemia in humans. J Clin Endocrinol Metab. (1981) 52:1235–41. 10.1210/jcem-52-6-1235
    1. Dunser MW, Hasibeder WR. Sympathetic overstimulation during critical illness: adverse effects of adrenergic stress. J Intensive Care Med. (2009) 24:293–316. 10.1177/0885066609340519
    1. Blumberg D, Hochwald S, Burt M, Donner D, Brennan MF. Tumor necrosis factor alpha stimulates gluconeogenesis from alanine in vivo. J Surg Oncol. (1995) 59:220–4; discussion 4–5. 10.1002/jso.2930590404
    1. Lang CH, Dobrescu C, Meszaros K. Insulin-mediated glucose uptake by individual tissues during sepsis. Metabolism. (1990) 39:1096–107. 10.1016/0026-0495(90)90172-9
    1. Ishizuka K, Usui I, Kanatani Y, Bukhari A, He J, Fujisaka S, et al. . Chronic tumor necrosis factor-alpha treatment causes insulin resistance via insulin receptor substrate-1 serine phosphorylation and suppressor of cytokine signaling-3 induction in 3T3-L1 adipocytes. Endocrinology. (2007) 148:2994–3003. 10.1210/en.2006-1702
    1. He J, Usui I, Ishizuka K, Kanatani Y, Hiratani K, Iwata M, et al. . Interleukin-1alpha inhibits insulin signaling with phosphorylating insulin receptor substrate-1 on serine residues in 3T3-L1 adipocytes. Mol Endocrinol. (2006) 20:114–24. 10.1210/me.2005-0107
    1. Klein J, Fasshauer M, Ito M, Lowell BB, Benito M, Kahn CR. beta(3)-adrenergic stimulation differentially inhibits insulin signaling and decreases insulin-induced glucose uptake in brown adipocytes. J Biol Chem. (1999) 274:34795–802. 10.1074/jbc.274.49.34795
    1. Deibert DC, DeFronzo RA. Epinephrine-induced insulin resistance in man. J Clin Invest. (1980) 65:717–21. 10.1172/JCI109718
    1. Dimitriadis G, Leighton B, Parry-Billings M, Sasson S, Young M, Krause U, et al. . Effects of glucocorticoid excess on the sensitivity of glucose transport and metabolism to insulin in rat skeletal muscle. Biochem J. (1997) 321:707–12. 10.1042/bj3210707
    1. Dresner A, Laurent D, Marcucci M, Griffin ME, Dufour S, Cline GW, et al. . Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest. (1999) 103:253–9. 10.1172/JCI5001
    1. Kelley DE, Mokan M, Simoneau JA, Mandarino LJ. Interaction between glucose and free fatty acid metabolism in human skeletal muscle. J Clin Invest. (1993) 92:91–8. 10.1172/JCI116603
    1. Kloner RA, Przyklenk K, Whittaker P. Deleterious effects of oxygen radicals in ischemia/reperfusion. Resolved and unresolved issues. Circulation. (1989) 80:1115–27. 10.1161/01.CIR.80.5.1115
    1. Nian M, Lee P, Khaper N, Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res. (2004) 94:1543–53. 10.1161/01.RES.0000130526.20854.fa
    1. Su H, Ji L, Xing W, Zhang W, Zhou H, Qian X, et al. . Acute hyperglycaemia enhances oxidative stress and aggravates myocardial ischaemia/reperfusion injury: role of thioredoxin-interacting protein. J Cell Mol Med. (2013) 17:181–91. 10.1111/j.1582-4934.2012.01661.x
    1. Mohanty P, Hamouda W, Garg R, Aljada A, Ghanim H, Dandona P. Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes. J Clin Endocrinol Metab. (2000) 85:2970–3. 10.1210/jcem.85.8.6854
    1. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, et al. . Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. (2002) 106:2067–72. 10.1161/
    1. Mapanga RF, Joseph D, Symington B, Garson KL, Kimar C, Kelly-Laubscher R, et al. . Detrimental effects of acute hyperglycaemia on the rat heart. Acta Physiol (Oxf). (2014) 210:546–64. 10.1111/apha.12184
    1. Kersten JR, Schmeling TJ, Orth KG, Pagel PS, Warltier DC. Acute hyperglycemia abolishes ischemic preconditioning in vivo. Am J Physiol. (1998) 275:H721–5. 10.1152/ajpheart.1998.275.2.H721
    1. Baranyai T, Nagy CT, Koncsos G, Onodi Z, Karolyi-Szabo M, Makkos A, et al. . Acute hyperglycemia abolishes cardioprotection by remote ischemic perconditioning. Cardiovasc Diabetol. (2015) 14:151. 10.1186/s12933-015-0313-1
    1. Malfitano C, Alba Loureiro TC, Rodrigues B, Sirvente R, Salemi VM, Rabechi NB, et al. . Hyperglycaemia protects the heart after myocardial infarction: aspects of programmed cell survival and cell death. Eur J Heart Fail. (2010) 12:659–67. 10.1093/eurjhf/hfq053
    1. Schaffer SW, Croft CB, Solodushko V. Cardioprotective effect of chronic hyperglycemia: effect on hypoxia-induced apoptosis and necrosis. Am J Physiol Heart Circ Physiol. (2000) 278:H1948–54. 10.1152/ajpheart.2000.278.6.H1948
    1. Qiu C, Sui J, Zhang Q, Wei P, Wang P, Fu Q. Relationship of endothelial cell-specific molecule 1 level in stress hyperglycemia patients with acute ST-segment elevation myocardial infarction: a pilot study. Angiology. (2016) 67:829–34. 10.1177/0003319715621996
    1. Morohoshi M, Fujisawa K, Uchimura I, Numano F. The effect of glucose and advanced glycosylation end products on IL-6 production by human monocytes. Ann N Y Acad Sci. (1995) 748:562–70. 10.1111/j.1749-6632.1994.tb17362.x
    1. Morohoshi M, Fujisawa K, Uchimura I, Numano F. Glucose-dependent interleukin 6 and tumor necrosis factor production by human peripheral blood monocytes in vitro. Diabetes. (1996) 45:954–9. 10.2337/diabetes.45.7.954
    1. Pandolfi A, Giaccari A, Cilli C, Alberta MM, Morviducci L, De Filippis EA, et al. . Acute hyperglycemia and acute hyperinsulinemia decrease plasma fibrinolytic activity and increase plasminogen activator inhibitor type 1 in the rat. Acta Diabetol. (2001) 38:71–6. 10.1007/s005920170016
    1. Ceriello A, Giugliano D, Quatraro A, Russo PD, Marchi E, Torella R. Hyperglycemia may determine fibrinopeptide a plasma level increase in humans. Metabolism. (1989) 38:1162–3. 10.1016/0026-0495(89)90152-2
    1. Ceriello A, Giugliano D, Quatraro A, Dello Russo P, Torella R. Blood glucose may condition factor VII levels in diabetic and normal subjects. Diabetologia. (1988) 31:889–91. 10.1007/BF00265372
    1. D'Onofrio N, Sardu C, Paolisso P, Minicucci F, Gragnano F, Ferraraccio F, et al. . MicroRNA-33 and SIRT1 influence the coronary thrombus burden in hyperglycemic STEMI patients. J Cell Physiol. (2020) 235:1438–52. 10.1002/jcp.29064
    1. Bauters C, Ennezat PV, Tricot O, Lauwerier B, Lallemant R, Saadouni H, et al. . Stress hyperglycaemia is an independent predictor of left ventricular remodelling after first anterior myocardial infarction in non-diabetic patients. Eur Heart J. (2007) 28:546–52. 10.1093/eurheartj/ehl546
    1. Zhu Y, Liu K, Meng S, Jia R, Lei X, Chen M, et al. . Augmented glycaemic gap is a marker for an increased risk of post-infarct left ventricular systolic dysfunction. Cardiovasc Diabetol. (2020) 19:101. 10.1186/s12933-020-01075-8

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner